Acute Liver Failure

Acute liver failure (ALF) is defined as coagulopathy — an international normalized ratio (INR) of 1.5 or greater — together with any degree of hepatic encephalopathy, occurring within 26 weeks of the onset of illness in a patient with no evidence of pre-existing cirrhosis.^[1] A small number of conditions are recognized exceptions to the "no pre-existing cirrhosis" rule because they can present as ALF on top of previously unrecognized chronic liver disease: Wilson disease, reactivation of chronic hepatitis B, and autoimmune hepatitis.^[2] ALF is further described by the interval between jaundice onset and encephalopathy onset — hyperacute (0-7 days; classically acetaminophen, ischemic hepatitis, or hepatitis A/E), acute (8-28 days), and subacute (29 days to 26 weeks; classically idiosyncratic drug-induced liver injury, seronegative/indeterminate hepatitis, or Wilson disease) — a distinction that matters because hyperacute presentations carry a higher risk of cerebral edema but a better chance of spontaneous (transplant-free) recovery, while subacute presentations carry a lower cerebral edema risk but a worse chance of spontaneous recovery.^[3] Acetaminophen (paracetamol) toxicity is the single leading cause of ALF in North America, and idiosyncratic drug-induced liver injury (DILI) — most often from antituberculous therapy, anticonvulsants, certain antibiotics, or herbal/dietary supplements — is one of the next most common identifiable causes, which places pharmacists in a genuinely front-line position for both recognizing an emerging case and directing its specific antidotal treatment.^[4]

Scleral icterus — yellowing of the sclera — in a child with jaundice from hemolytic anemia; the sclera often shows visible yellowing before skin discoloration becomes obvious, making it a key early sign to look for on exam. (Sab3el3eish, CC BY 3.0, Wikimedia Commons)

Typical evolution

ALF typically begins with a nonspecific prodrome — nausea, anorexia, malaise, right upper quadrant discomfort — that is easy to dismiss, followed by jaundice, and then by the two findings that define the syndrome: coagulopathy (easy bruising, mucosal bleeding, oozing from venipuncture sites) and hepatic encephalopathy (from subtle personality change through to coma). The degree of aminotransferase elevation does not reliably predict severity or outcome — synthetic function (INR) and mental status are what determine severity, not how high ALT/AST climbed.

Hepatic encephalopathy grading (West Haven criteria)

Grade III-IV encephalopathy is the threshold at which cerebral edema and intracranial hypertension become a real, immediate risk — this is the point at which airway protection, ICU-level neuro-monitoring, and active management of intracranial pressure become urgent (see Red Flags & Refer and Choose Initial Treatment).^[1]

Signs of evolving cerebral edema / raised intracranial pressure

Systemic hypertension with bradycardia, abnormal pupillary responses, decorticate/decerebrate posturing, and papilledema can all indicate rising intracranial pressure in a patient with grade III-IV encephalopathy — a late-stage, life-threatening development that needs immediate escalation rather than routine reassessment.

Acetaminophen-induced ALF

• Intentional single large overdose.
• "Therapeutic misadventure" — repeated supratherapeutic dosing over days, often from combination opioid-acetaminophen products taken for genuine pain, or from stacking multiple acetaminophen-containing products without realizing it — is a distinct and easily missed risk pattern; it does not fit the single-ingestion Rumack-Matthew nomogram (see Assessment & Diagnosis).
• Chronic alcohol use, malnutrition, or a fasting/low-glycogen state — all lower glutathione stores and increase susceptibility to hepatotoxicity at doses that would otherwise be considered safe.
• Concurrent use of other CYP2E1-inducing or hepatotoxic agents.

Idiosyncratic drug-induced liver injury (DILI)

• Antituberculous therapy — isoniazid, alone or combined with rifampin, is one of the most commonly implicated agents; risk rises with age, alcohol use, and slow-acetylator genotype.
• Anticonvulsants — valproate carries a particular risk of severe, sometimes fatal hepatotoxicity, highest in young children and in those with an underlying mitochondrial disorder.
• Antibiotics — amoxicillin-clavulanate is among the most frequently implicated drugs in DILI registries generally (though its liver injury is more often cholestatic than fulminant); nitrofurantoin and certain sulfonamides are other recognized culprits.
• Herbal and dietary supplements — a genuinely underappreciated and under-reported cause; bodybuilding/anabolic supplements, weight-loss products, and certain "green tea extract" or kava-containing products are specifically implicated.^[4]
• Polypharmacy and genetic susceptibility (specific HLA haplotypes are increasingly recognized as risk markers for particular drugs).
• Pre-existing chronic liver disease, which both increases DILI risk and increases the severity of a superimposed episode.

Other causes and their risk factors

• Viral hepatitis A, B, or E (hepatitis E particularly in pregnancy and in those exposed to undercooked pork/game).
• Autoimmune hepatitis — can present acutely, more often in women.
• Ischemic hepatitis ("shock liver") — recent hypotension, cardiac arrest, or severe heart failure.
• Wilson disease — consider specifically in patients under 40, especially with a low alkaline phosphatase relative to bilirubin and a Coombs-negative hemolytic anemia.
• Acute fatty liver of pregnancy or HELLP syndrome — third-trimester pregnancy.
• Amanita phalloides and related mushroom ingestion.
• Budd-Chiari syndrome (hepatic venous outflow obstruction) — underlying prothrombotic states.
• In up to about 15% of cases despite full work-up, no cause is ever identified (indeterminate/seronegative ALF).

Confirming the diagnosis

• INR ≥1.5 plus any grade of hepatic encephalopathy, illness duration <26 weeks, and no pre-existing cirrhosis (exceptions: Wilson disease, reactivated chronic hepatitis B, autoimmune hepatitis).^[1]
• A history for exposures: every medication, supplement, and herbal/natural health product taken in the preceding weeks (dose, duration, timing), alcohol use, recent travel, mushroom foraging/ingestion, and any recent hypotensive or cardiac arrest event.

Core laboratory work-up

• INR/PT, CBC, comprehensive metabolic panel (including glucose and creatinine), lactate, and arterial blood gas.
• Venous or arterial ammonia — correlates only loosely with encephalopathy grade but a markedly elevated arterial level is a useful early warning for cerebral edema risk.
• Acetaminophen level plus a full urine/serum toxicology screen for co-ingestants — check in every ALF patient regardless of the stated history, since unwitnessed or denied acetaminophen ingestion is common.
• Viral serologies: anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HCV/HCV RNA, anti-HEV (particularly in pregnancy or after relevant travel/exposure); consider HSV and VZV PCR in an unexplained case, especially if immunocompromised or pregnant.
• Autoimmune markers (ANA, anti-smooth-muscle antibody, immunoglobulin levels), and in patients under 40, ceruloplasmin plus a 24-hour urine copper if Wilson disease is a possibility (a low alkaline phosphatase-to-bilirubin ratio and Coombs-negative hemolytic anemia are supportive clues).
• Pregnancy test in every patient of childbearing potential.
• Abdominal Doppler ultrasound to assess liver size and rule out hepatic venous outflow obstruction (Budd-Chiari) or biliary obstruction.
• Liver biopsy is not required to make the diagnosis and is rarely pursued acutely given the coagulopathy; when histology is genuinely needed to resolve an unclear etiology, a transjugular (rather than percutaneous) approach is used specifically because of the bleeding risk.

Etiology at a glance

For suspected DILI specifically, the ACG guideline suggests a prognostic model combining MELD score, Charlson comorbidity index, and serum albumin to help estimate 6-month mortality and inform how urgently to escalate care.^[5]

• Identify a specifically treatable cause promptly, and start N-acetylcysteine without delay whenever acetaminophen toxicity is possible.
• Stop any hepatotoxic drug or supplement immediately once DILI is suspected — this is the single most important intervention in DILI.
• Prevent and manage the major complications: cerebral edema, coagulopathy-related bleeding, infection, renal failure, and hypoglycemia.
• Determine transplant candidacy early — via King's College Criteria and ongoing hepatology/transplant-centre judgment — rather than waiting for irreversible deterioration.
• Provide ICU-level supportive care to maximize the chance of either spontaneous recovery or a successful bridge to transplantation.

• ICU-level monitoring for any patient with grade II or higher encephalopathy.
• Head-of-bed elevation to 30 degrees and a low-stimulation environment once encephalopathy reaches grade III-IV.
• Avoid unnecessary sedation — it masks the neurologic exam and can precipitate or worsen encephalopathy.
• Maintain adequate nutrition — enteral feeding with protein intake of roughly 1.0-1.5 g/kg/day; protein restriction is outdated and not recommended, since it does not reliably improve encephalopathy and worsens nutritional status.
• Gut decontamination for a large or recent ingestion: activated charcoal if within about 1-2 hours of ingestion (or later for an extended-release product or a co-ingestant that delays gastric emptying); whole bowel irrigation is an option for extended-release acetaminophen or a co-ingested enteric-coated/sustained-release product.
• Avoid unnecessary invasive procedures given the coagulopathy; when a procedure is required, plan it around correction of coagulopathy rather than around routine correction beforehand.
• Early and repeated communication with a liver transplant centre — this is itself a core part of management, not an afterthought once the patient has deteriorated.

Pregnancy

Third-trimester liver injury needs urgent evaluation for acute fatty liver of pregnancy (AFLP) and HELLP syndrome, both of which can cause or mimic ALF — hypoglycemia and coagulopathy out of proportion to the degree of transaminase elevation point toward AFLP, while hemolysis, elevated liver enzymes, and low platelets point toward HELLP. Delivery is the definitive treatment for both and should not be delayed for further liver-specific work-up once either is suspected. Hepatitis E also carries a disproportionately severe course in pregnancy. N-acetylcysteine is considered safe in pregnancy for acetaminophen toxicity — the risk to the fetus from untreated maternal toxicity far outweighs any risk from NAC itself.

Pediatrics

The etiology distribution differs from adults: indeterminate/seronegative hepatitis and inherited metabolic disease are relatively more common causes in children, and acetaminophen and DILI are relatively less dominant than in adults, though still important. King's College Criteria were derived in and validated mainly for adults and perform less reliably in children — pediatric-specific prognostic scoring is used at specialized centres. NAC dosing is weight-based using the same mg/kg regimen as adults.

Renal impairment

N-acetylcysteine dosing does not require renal adjustment. Avoid other nephrotoxic drugs where possible. Continuous renal replacement therapy is preferred over intermittent hemodialysis if renal support is needed, given better hemodynamic and intracranial-pressure stability.

Obesity

Weight-based NAC dosing in a patient over roughly 100 kg should be capped or calculated using an adjusted body weight per current toxicology-consensus guidance, rather than dosed on actual body weight without limit — uncapped dosing in a larger patient increases nausea/vomiting and anaphylactoid reaction risk without added benefit.^[6]

Older adults

Reduced hepatic functional reserve and a higher burden of comorbidity both lower the threshold for early transplant-centre involvement and can affect ultimate transplant candidacy — involve the transplant team early rather than waiting to see whether an older patient "declares" a clearly poor trajectory.

• Neurologic/encephalopathy-grade checks at least every 1-2 hours in any patient with grade II or higher encephalopathy, or with any downward trend.
• Serial INR, glucose, lactate, electrolytes, and renal function — frequency guided by severity and trend (as often as every few hours in a rapidly evolving case, less often once clearly stabilizing).
• Serial ammonia is reasonable in a patient with evolving or worsening encephalopathy, recognizing its correlation with encephalopathy grade is imperfect.
• Continue N-acetylcysteine and monitoring for acetaminophen-induced injury until acetaminophen is undetectable and INR/encephalopathy are clearly improving from their worst point, not simply until the scheduled infusion ends.
• Low threshold for repeat cultures and clinical reassessment for infection at any sign of deterioration.
• Invasive intracranial pressure monitoring is used selectively at specialized centres given its own bleeding risk in a coagulopathic patient; non-invasive approaches (e.g., optic nerve sheath diameter ultrasound, clinical/imaging assessment) are used more often as a lower-risk alternative.
• Reassess transplant candidacy daily — King's College Criteria status can change quickly in either direction.

1. Worsening INR, encephalopathy grade, or new signs of cerebral edema despite N-acetylcysteine and supportive care — escalate immediately to the transplant centre and expedite listing evaluation rather than continuing routine monitoring.
2. King's College Criteria met — expedite transplant listing; remember the criteria's imperfect sensitivity means a patient who does not meet them can still be deteriorating and warrants continued close involvement of the transplant team rather than reassurance.^[1]
3. Refractory intracranial hypertension despite hypertonic saline and mannitol — consider second-tier measures (e.g., targeted temperature management/mild hypothermia, or other specialist-directed interventions) under critical-care/hepatology direction; these are not first-line and should not be attempted outside a specialized setting.
4. Not a transplant candidate (irreversible multi-organ failure, or another absolute contraindication) — shift the goals-of-care conversation toward comfort-focused management rather than continuing maximal interventions indefinitely.
5. Etiology remains indeterminate despite a complete work-up — consider transjugular liver biopsy to help clarify diagnosis and guide any etiology-specific therapy (e.g., corticosteroids for an autoimmune-hepatitis-like picture) under specialist direction.

• Waiting for a confirmatory acetaminophen level, or for transaminases to become dramatically abnormal, before starting N-acetylcysteine — start based on a compelling ingestion history and treat while confirmatory results are pending.
• Applying the Rumack-Matthew nomogram to a staggered/repeated-ingestion or unknown-timing overdose — the nomogram is only valid for a single, acute, known-time ingestion; use a lower, non-nomogram treatment threshold instead.^[6]
• Stopping N-acetylcysteine at the end of the standard protocol duration in a patient who has already progressed to ALF — continue until encephalopathy resolves, INR normalizes, or transplantation occurs.
• Correcting an elevated INR prophylactically with FFP or vitamin K outside of active bleeding or an imminent procedure — this destroys a key prognostic marker without a clinical benefit.
• Treating a persistently elevated INR after a single vitamin K dose as a "dosing failure" rather than recognizing it as true synthetic liver failure and a red flag for urgent referral.
• Missing chronic supratherapeutic acetaminophen dosing ("therapeutic misadventure") as a cause because the presentation doesn't look like a classic single overdose.
• Failing to check an acetaminophen level in every ALF patient regardless of the stated history — unwitnessed or denied ingestion is common.
• Rechallenging a patient with a suspected DILI-causing drug to "confirm" the diagnosis.
• Missing Wilson disease in a young patient, or acute fatty liver of pregnancy/HELLP in a third-trimester patient, because the presentation was assumed to be viral or drug-induced by default.
• Using benzodiazepines liberally for agitation in a patient with hepatic encephalopathy — they accumulate in liver failure and can precipitate or mask worsening encephalopathy (see Drug Tables).
• Delaying first contact with a liver transplant centre until the patient has already deteriorated significantly — early contact is the default even when the patient ultimately does not need transplantation.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

N-acetylcysteine dosing protocols (acetaminophen toxicity, and consider in early-grade non-acetaminophen ALF)

Give with an antihistamine and slow the infusion rate for an anaphylactoid reaction (rash, flushing, bronchospasm, hypotension) rather than stopping treatment unless the reaction is severe.

Coagulopathy and cerebral edema management

Do not correct INR prophylactically outside active bleeding or an imminent procedure — it is a prognostic marker, not simply a lab value to normalize.

Common idiosyncratic DILI culprits pharmacists should recognize

A diagnosis of exclusion — stop the suspected agent immediately once DILI is suspected; do not wait for the full work-up to be complete.

Medications to avoid or dose-adjust once liver failure is present

Impaired hepatic clearance, reduced protein binding from hypoalbuminemia, and the risk of masking or worsening encephalopathy all argue for a lower threshold to avoid or reduce these agents.

Etiology-specific and adjunct therapies